Puma Biotechnology, Inc. (NASDAQ:PBYI) announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee (ODAC) on May 24, 2017. Neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen.
Puma Biotechnology, Inc. (NASDAQ:PBYI) shares ticked up 11.08% to $39.60 on Monday.
ODAC is an independent panel of experts that evaluates data concerning the efficacy and safety of marketed and investigational products for use in the treatment of cancer and makes appropriate recommendations to the FDA. Although the FDA will consider the recommendation of the panel, the final decision regarding the approval of the product is made by the FDA solely, and the recommendations by the panel are non-binding.
Technical Stock Analysis
Shares outstanding are recorded as 36.95 million and total shares floated are 31.80 million. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 6.30. Company’s distance from 20 day simple moving average is 4.01% and distance from 50-Day simple moving average is 5.36%.
Best time to invest in stock market is when things are on odd side, and it’s not easy how to pick stocks. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 2 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for PBYI is $64.60 while analysts mean recommendation is 1.90.
Puma Biotechnology, Inc. (NASDAQ:PBYI) yearly performance is 24.33%. Annual EPS Growth of past 5 years is -44.40%. The current share price indicates that stock is -45.95% away from its one year high and is moving 100.61% ahead of its 52-week low.
NV5 Global, Inc. (NASDAQ:NVEE) announced that it has acquired Bock & Clark Corporation (“Bock & Clark”), an established American Land Title Association (ALTA) surveying, commercial zoning, and environmental services firm based in Akron, Ohio. Bock & Clark has eight offices in the U.S. and annual revenues of approximately $39 million. The company was purchased entirely in cash with the exception of restricted stock granted to key employees and will be immediately accretive to NV5’s earnings.
On 17 April 2017, NV5 Global, Inc. (NASDAQ:NVEE) shares moved to $37.60 after starting the day at $36.55. Stock has got OUTPERFORM rating from 3 analysts of Thomson Reuters, no analyst given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for NVEE is $42.50 while analysts mean recommendation is 1.80.
At the movement Whiting Petroleum Corporation (NYSE:WLL) is under coverage by number of analysts. Buy rating has been given by 7 analysts to the company stock whereas no analyst given UNDERPERFORM rating to stock and 20 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Hold and their mean rating for the stock is 2.53 on scale of 1-5. Analysts mean target price for Whiting Petroleum Corporation (NYSE:WLL) is $13.60 while their mean recommendation is 2.50 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved ticked up 1.40% to end the day at $8.68. The current share price indicate that stock is -39.89% away from its one year high and is moving 36.05% ahead of its 52-week low.